Month: September 2020

I have great fun & satisfaction mentoring @IU_Health residents interested in #re…

I have great fun & satisfaction mentoring @IU_Health residents interested in #retina & #research. Congrats to these fantastic current & prior IU residents for this recent publication on a most-feared complication of #eye surgery:https://t.co/De83FjWyks Source by Thomas Ciulla, MD, MBA Return to main website.

At this year’s Retina Society meeting, our team & colleagues had numerous presen…

At this year’s Retina Society meeting, our team & colleagues had numerous presentations on #retina clinical science as well as #suprachoroidal delivery of tyrosine kinase inhibitor, #genetherapy & corticosteroid. #eyes #ophthalmology #biotech #medicine #clinicalresearch #macula https://t.co/gyCPxPE17z Source by Thomas Ciulla, MD, MBA Return to main […]

Diabetic macular edema treatment burden remains a significant barrier to meaning…


Diabetic macular edema treatment burden remains a significant barrier to meaningfully positive real world outcomes. Longer acting and more effective treatments are needed…#diabetes #retina #eyes #clinicaltrials https://t.co/IhJVFCnOCZ


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @1stOncology: #AuraBiosciences Announces Dosing of First Patient in Phase 2 S…

RT @1stOncology: #AuraBiosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of #AU011 in… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @PharmacDaily: Clearside Biomedical’s Oncology Licensing Partner Doses First …

RT @PharmacDaily: Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Mel… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @OphthTimes: . @REGENXBIO announces dosing of first patient in AAVIATE phase…


RT @OphthTimes: . @REGENXBIO announces dosing of first patient in AAVIATE phase II trial of RGX-314 for treatment of wet AMD using suprac…


Source by Thomas Ciulla, MD, MBA

Return to main website.

Just co-authored this paper on integrin inhibition, a potentially important path…

Just co-authored this paper on integrin inhibition, a potentially important pathway for treatment of common causes of vision loss, #maculardegeneration and #diabeticretinopathy… #retina #ophthalmology #eyes #diabetes #biotech #drugdevelopment #medicine https://t.co/qI3dJQ8ya1 Source by Thomas Ciulla, MD, MBA Return to main website.

RT @MDMagazine: .@REGENXBIO yesterday announced the clearance of the Investigati…

RT @MDMagazine: .@REGENXBIO yesterday announced the clearance of the Investigational New Drug application by the #FDA to evaluate suprachor… Source by Thomas Ciulla, MD, MBA Return to main website.

Recently interviewed for this article on #GeneTherapy: …


Recently interviewed for this article on #GeneTherapy: https://t.co/UtFxhmVPQ8


Source by Thomas Ciulla, MD, MBA

Return to main website.